Shares of Johnson & Johnson (JNJ) are down by 61 cents, or 1%, at $62.61 after the company this morning reported Q4 sales and profit above expectations but forecast this year’s profit shy of analysts’ forecasts.
Q4 revenue rose 9% to $16.6 billion, the company reported, ahead of the $15.7 billion analysts were expecting. Profit per share came in at $1.02, excluding some charges, which was ahead of the 97-cent estimate.
International sales clearly outshone domestic, with overseas sales to consumers up 15% in the quarter versus just 3% growth in the U.S. Likewise, in the pharmaceutical division, overseas sales rose 17.7% while they dipped 2.7% in the States.
For this year, J&J foresees $4.85 to $4.95 per share, excluding some costs, which at the midpoint is actually below the $4.94 average estimate.
J&J chair and CEO William C. Weldon said the company was well positioned for “continued leadership and growth in global healthcare” in 2010.
No comments:
Post a Comment